4 completed, 3 active not recruiting, 3 recruiting, 1 terminated. 11 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 4, Active not recruiting 3, Recruiting 2, Terminated 1, Unknown 1 |
| Phase 2 | 7 | Recruiting 3, Active not recruiting 2, Completed 1, Unknown 1 |
Follow Adagene Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer ADG126, Pembrolizumab - Locally Advanced Colorectal Cancer | Phase 2 | Recruiting | National University Hospital, Singapore | 20 | 2025-04-14 | 2025-07-25 |
| Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer Pembrolizumab & ADG106 (Phase Ib), Pembrolizumab & ADG106 (Phase II) - Advanced Solid Tumor, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | National University Hospital, Singapore | 51 | 2023-06-12 | 2025-07-25 |
| Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors ADG206 - Advanced/Metastatic Solid Tumors | Phase 1 | Active not recruiting | Adagene Inc | 14 | 2023-02-13 | 2026-01-08 |
| ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors ADG126, Pembrolizumab (KEYTRUDA®), Standard of Care (Trifluridine/Tipiracil-Bevacizumab) - Advanced/Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Adagene Inc | 186 | 2022-06-15 | 2026-11-02 |
| A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer ADG106, Doxorubicin, Cyclophosphamide - HER2-negative Breast Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | National University Hospital, Singapore | 66 | 2022-05-19 | 2025-07-25 |
| ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors ADG116 - Advanced/Metastatic Solid Tumors | Phase 1 | Completed | Adagene Inc | 6 | 2022-02-09 | 2024-02-26 |
| A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC Nivolumab, ADG106 - Metastatic Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | National University Hospital, Singapore | 53 | 2021-11-12 | 2022-03-25 |
| ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors ADG126 Mono, ADG126-anti PD1, ADG126-ADG106 - Advanced/Metastatic Solid Tumors | Phase 1 / Phase 2 | Completed | Adagene Inc | 58 | 2021-03-15 | 2024-08-14 |
| A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab - Advanced Liver Cancers | Phase 1 / Phase 2 | Active not recruiting | Hoffmann-La Roche | 518 | 2020-11-01 | 2026-09-03 |
| A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients ADG116, ADG106, anti PD1 drug - Advanced/Metastatic Solid Tumors | Phase 1 | Completed | Adagene Inc | 72 | 2020-09-23 | 2026-01-08 |
| Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors ADG116 - Solid Tumor | Phase 1 | Terminated | Adagene Inc | 1 | 2019-08-29 | 2021-09-10 |
| Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma ADG106 - Solid Tumors, Non-Hodgkin Lymphoma | Phase 1 | Completed | Adagene Inc | 49 | 2018-09-17 | 2022-10-18 |
Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Triple Negative Breast Neoplasms (1)
pembrolizumab (4) · Bevacizumab (2) · Clinical Trials, Phase II as Topic (1) · Cyclophosphamide (1) · Doxorubicin (1) · HMPL-013 (1) · Nivolumab (1) · Paclitaxel (1) · Standard of Care (1) · Tiragolumab (1) · Trifluridine (1) · atezolizumab (1) · tocilizumab (1) · trifluridine tipiracil drug combination (1)
United States (7) · Singapore (5) · Australia (3) · China (2) · South Korea (2) · France (1) · Israel (1) · New Zealand (1) · Taiwan (1)
Soo Chin Lee (2) · Boon Cher Goh (1) · Jiping Zha, MD (1) · Jiping Zha, MD, PhD (1) · Wei Peng Yong, MD (1)
PMID 26773716, PMID 29692997, PMID 30627694, PMID 31105267, PMID 32489249, PMID 33207944, PMID 38172595, PMID 39855251, PMID 9779724